Document Detail


Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
MedLine Citation:
PMID:  12297762     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: ERCP is frequently complicated by pancreatitis. The aims of this study were to assess the efficacy of somatostatin and gabexate for prevention of post-ERCP pancreatitis in high-risk patients and to determine predisposing factors for post-ERCP pancreatitis. A meta-analysis was conducted of all published studies on the use of somatostatin or gabexate for prevention of post-ERCP pancreatitis. METHODS: A double blind, multicenter, placebo-controlled trial was conducted in patients at high risk for post-ERCP pancreatitis. Patients were randomized to receive an intravenous infusion of somatostatin (750 mg), gabexate (500 mg), or placebo that was started 30 minutes before endoscopy and continued for 2 hours afterward. Patients were evaluated clinically and serum amylase levels determined at 4 and 24 hours after endoscopy. RESULTS: No significant difference in the occurrence of pancreatitis, hyperamylasemia, or abdominal pain was observed among placebo-, gabexate-, and somatostatin-treated patients. A sphincterotomy longer than 2 cm (p = 0.0001), more than 3 pancreatic injections (p = 0.0001), and unsuccessful cannulation (p = 0.008) were predictive of post-ERCP pancreatitis. Hyperamylasemia was predicted by more than 3 pancreatic injections (p = 0.0001) and sphincterotomy (p = 0.02). The meta-analysis of trials of short-term infusion of gabexate or somatostatin did not show efficacy for either drug. CONCLUSIONS: Short-term administration of gabexate or somatostatin in patients at high risk for pancreatitis is ineffective for prevention of ERCP-induced pancreatitis. Pancreatic injury is related to maneuvers used to obtain biliary access rather than to any patient characteristic or endoscopist experience.
Authors:
Angelo Andriulli; Rocco Clemente; Luigi Solmi; Vittorio Terruzzi; Renzo Suriani; Angelo Sigillito; Gioacchino Leandro; Pietro Leo; Giovanni De Maio; Francesco Perri
Publication Detail:
Type:  Clinical Trial; Comparative Study; Evaluation Studies; Journal Article; Meta-Analysis; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Gastrointestinal endoscopy     Volume:  56     ISSN:  0016-5107     ISO Abbreviation:  Gastrointest. Endosc.     Publication Date:  2002 Oct 
Date Detail:
Created Date:  2002-09-25     Completed Date:  2002-12-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0010505     Medline TA:  Gastrointest Endosc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  488-95     Citation Subset:  IM    
Affiliation:
Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adult
Cholangiopancreatography, Endoscopic Retrograde / adverse effects*
Clinical Competence
Double-Blind Method
Female
Gabexate / therapeutic use*
Hormones / therapeutic use*
Humans
Hyperamylasemia / blood
Male
Meta-Analysis as Topic
Middle Aged
Pancreatitis / etiology*,  prevention & control*
Placebo Effect
Preoperative Care / methods*
Prospective Studies
Risk Factors
Serine Proteinase Inhibitors / therapeutic use*
Somatostatin / therapeutic use*
Sphincterotomy, Endoscopic
Treatment Outcome
Chemical
Reg. No./Substance:
0/Hormones; 0/Serine Proteinase Inhibitors; 39492-01-8/Gabexate; 51110-01-1/Somatostatin
Comments/Corrections
Comment In:
Gastrointest Endosc. 2003 Nov;58(5):816   [PMID:  14997914 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Detection of high-grade dysplasia in Barrett's esophagus by spectroscopy measurement of 5-aminolevul...
Next Document:  Clinical outcomes in patients who undergo extracorporeal shock wave lithotripsy for chronic calcific...